« Back
Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 6, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 2:05 p.m. EDT. The presentation will be webcast live and available for replay from the Investors section of the Seattle Genetics website at www.seattlegenetics.com.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs and is commercially available globally in 67 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing enfortumab vedotin, an ADC in a planned pivotal trial for metastatic urothelial cancer, in collaboration with Astellas and tisotumab vedotin, an ADC in a phase 1/2 trial for solid tumors, in collaboration with Genmab. Headquartered in Bothell, Washington and with European and international operations in Zug, Switzerland, Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

Source: Seattle Genetics, Inc.

Seattle Genetics, Inc.
Investors
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
or
Media
Brandi Robinson, 425-527-2910
brobinson@seagen.com